Palbociclib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2609 publications
Treatment outcomes with palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer who also have cardiovascular diseases: a plain language summary.
Journal: Future oncology (London, England)
Published: June 22, 2026
Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary.
Journal: Future oncology (London, England)
Published: June 22, 2026
Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 04, 2026
Wip1 Inhibition Enhances the Therapeutic Efficacy of Palbociclib in Luminal A Breast Cancer by Modulating Cell Cycle Progression and Apoptosis.
Journal: Folia biologica
Published: May 20, 2026
Predictors of hepatotoxicity in patients receiving CDK4/6 inhibitors: A real-world cohort study.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: May 14, 2026
An Extreme Clinical Diagnosis: Primary Metastatic Breast Cancer with Complete Bilateral Breast Contour Elimination and Ulceration.
Journal: Diagnostics (Basel, Switzerland)
Published: May 13, 2026
Circular-by-Design Zwitterionic Polyglycerol-Polyoxazoline-Lysine Pseudodendrimers as Multifunctional Antibacterial and Anticancer Drug Delivery Platforms.
Journal: Biomacromolecules
Published: May 07, 2026
Palbociclib for HR-Positive, HER2-Positive Breast Cancer.
Journal: The New England journal of medicine
Published: April 29, 2026
Palbociclib for HR-Positive, HER2-Positive Breast Cancer.
Journal: The New England journal of medicine
Published: April 29, 2026
Palbociclib for HR-Positive, HER2-Positive Breast Cancer. Reply.
Journal: The New England journal of medicine
Published: April 29, 2026
Last Updated: 06/30/2026